Notable Labs’ (NTBL) Market Outperform Rating Reiterated at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of Notable Labs (NASDAQ:NTBL) in a research note issued to investors on Monday morning, Benzinga reports. They currently have a $9.00 price objective on the stock.

Separately, Chardan Capital lowered their price objective on Notable Labs from $9.00 to $7.00 and set a buy rating for the company in a report on Monday.

Notable Labs Stock Performance

Shares of NASDAQ NTBL opened at $0.97 on Monday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.65 and a current ratio of 5.65. The stock has a market capitalization of $2.15 million, a price-to-earnings ratio of -0.27 and a beta of 0.77. Notable Labs has a 1 year low of $0.83 and a 1 year high of $11.20. The stock’s 50-day simple moving average is $1.43.

Hedge Funds Weigh In On Notable Labs

A hedge fund recently bought a new stake in Notable Labs stock. Industry Ventures L.L.C. bought a new stake in shares of Notable Labs, Ltd. (NASDAQ:NTBL) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 204,424 shares of the company’s stock, valued at approximately $386,000. Notable Labs comprises approximately 0.6% of Industry Ventures L.L.C.’s investment portfolio, making the stock its 6th biggest holding. Industry Ventures L.L.C. owned approximately 9.21% of Notable Labs as of its most recent SEC filing. Institutional investors and hedge funds own 70.48% of the company’s stock.

About Notable Labs

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic.